

ACTIVATED FACTOR VII/ FACTOR VIIa

OTHER NAMES	Activated Factor 7a, Factor 7a, Activated Factor VII, Factor VIIa, Eptacog Alfa Activate, Niastase®, NiaStase RT®
PRODUCT COMPOSITION	Activated recombinant human blood coagulation Factor VII
INFORMED CONSENT	Not required.
ALTERNATIVES	Non-blood Product: None Blood Product: None
DOSAGE	<ul style="list-style-type: none"> • Consultation with Hematopathologist is required for treatment of bleeding episodes • Treatment for patients with inhibitors may be ordered by a Hematologist without Hematopathologist consult. Ordered in milligrams and as a timed frequency (i.e. Q2h) • Transfusion Medicine (TM) will provide the dose requested rounded to the nearest milligram, dependant on available vial sizes. If a large difference between dose ordered and dose available exists, TM staff will consult with the ordering physician
ADMINISTRATION	<p>Factor VIIa is intended for intravenous bolus administration only. See product monograph.</p> <ul style="list-style-type: none"> • Reconstituted by TM and supplied to unit in a syringe • Product is best given immediately after preparation, MUST be within 3 hours of reconstitution • Should be inspected visually for particulate matter and discoloration prior to administration • IV bolus injection in 0.9 % NaCl ONLY • DO NOT mix with other IV solutions. • Usually 3-5mL over 3-5 minutes <p>Administer the entire amount</p>
DIAGNOSTIC MONITORING	<p>Vital sign monitoring as per hospital policy for any blood, blood component and other related product. In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.</p> <ul style="list-style-type: none"> • Patients should be kept under close observation for signs and symptoms of unfavorable activation of the coagulation system or thrombosis.
CLINICAL INDICATIONS	<ul style="list-style-type: none"> • Indicated in Hemophilia A/B with inhibitors to Factor VIII or Factor IX, or non-hemophiliacs with acquired inhibitors. • Treatment of bleeding episodes related to surgery.
SPECIAL CONSIDERATIONS	<ul style="list-style-type: none"> • TM will need approximately 30 minutes preparation time • N.B. NiaStase RT® immediately loses its activity when mixed with Ringers Lactate • TM needs prompt notification of changes of both dosage and/or frequency
STORAGE CONDITIONS	DO NOT REFRIGERATE AFTER RECONSTITUTION
REFERENCES	Review product monograph